by John Conrad | Jun 28, 2024 | NewsBrief
Meitheal Pharmaceuticals, a Chicago-based biopharmaceutical company, has made a significant move in the biosimilars market by acquiring exclusive U.S. commercial rights to YUSIMRY® (adalimumab-aqvh), a biosimilar of the widely-used drug Humira®. This strategic...
